ReviewArchives of neurology2010
New insights into susceptibility to glioma.
Review in Archives of neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- The TERT rs2736100 polymorphism and cancer risk: a meta-analysis based on 25 case-control studies.BMC cancer · 2012Pooled it
- A MGMT Enhancer Variant is Associated with Glioma Susceptibility and Progression.Cellular and molecular neurobiology · 2025Article
- Stem cell-derived neural organoids as platforms to investigate glioblastoma invasion and migration: A systematic review.World journal of stem cells · 2025Article
- Asian-specific 3'UTR variant in CDKN2B associated with risk of pituitary adenoma.Molecular biology reports · 2022Article
- Implications of risk conferred by 5p15.33 loci genetic variants; human telomerase reverse transcriptase rs2736098 and rs2736100 in predisposition of bladder cancer.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022Article
- Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers.International journal of molecular sciences · 2020Review
- Association of the CCDC26 rs4295627 polymorphism with the risk of glioma: Evidence from 7,290 cases and 11,630 controls.Molecular and clinical oncology · 2016Article
- Genetic Modulation of Neurocognitive Function in Glioma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Genetic variants in N-myc (and STAT) interactor and susceptibility to glioma in a Chinese Han population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- The CDKN2A-CDKN2B rs4977756 polymorphism and glioma risk: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- Interaction of allergy history and antibodies to specific varicella-zoster virus proteins on glioma risk.International journal of cancer · 2014Article
- Neuro-oncology: Five new things.Neurology. Clinical practice · 2013Article
- Genetic polymorphisms of DNA double-strand break repair pathway genes and glioma susceptibility.BMC cancer · 2013Article
- Functional impact bias reveals cancer drivers.Nucleic acids research · 2012Article
- Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system.Journal of the National Cancer Institute · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The study of inherited susceptibility to cancer has been one of the most informative areas of research in the past decade. Most of the cancer genetics studies have been focused on the common tumors such as breast and colorectal cancers. As the allelic architecture of these tumors is unraveled, research attention is turning to other rare cancers such as glioma, which are also likely to have a major genetic component as the basis of their development. In this brief review we discuss emerging data on glioma whole genome-association searches to identify risk loci. Two glioma genome-wide association studies have so far been reported. Our group identified 5 risk loci for glioma susceptibility (TERT rs2736100, CCDC26 rs4295627, CDKN2A/CDKN2B rs4977756, RTEL1 rs6010620, and PHLDB1 rs498872). Wrensch and colleagues provided further evidence to 2 risk loci (CDKN2B rs1412829 and RTEL1 rs6010620) for GBM and anaplastic astrocytoma. Although these data provide the strongest evidence to date for the role of common low-risk variants in the etiology of glioma, the single-nucleotide polymorphisms identified alone are unlikely to be candidates for causality. Identifying the causal variant at each specific locus and its biological impact now poses a significant challenge, contingent on a combination of fine mapping and functional analyses. Finally, we hope that a greater understanding of the biological basis of the disease will lead to the development of novel therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.